SCHEMBL1010860

SCHEMBL1010860

Cc1cccc(Oc2cccc(CCl)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.44
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
MAPT P10636 2/20 0.40
PPARG P37231 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
F10 P00742 4/20 0.39
GRM5 P41594 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
TTR P02766 1/20 0.38
MAP4K4 O95819 1/20 0.37
NPC1 O15118 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
FFAR1 O14842 2/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011422 0.84 F10 (0.46) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL18993112 0.82 PPARG (0.41) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL27209650 0.81 F2 (0.39) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL18993131 0.81 MCL1 (0.38) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL27233662 0.79 ALDH1A1 (0.38) CYP1A2CYP2C9CYP2C19MAPTL3MBTL1
SCHEMBL10544428 0.79 CYP1A2 (0.53) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL17720580 0.78 MAP4K4 (0.55) F2CYP1A2CYP2C9CYP2C19MAPT
Amelenodor SCHEMBL22061849 0.77 CCR1 (0.44) F2CYP1A2CYP2C9CYP2C19MAPT
SCHEMBL18422515 0.77 TTR (0.46) MAPTPPARGMEN1KMT2AHTT
SCHEMBL10546778 0.77 MEN1 (0.51) F2MAPTL3MBTL1F10GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC F2 448/4885CYP1A2 114/4885CYP2C9 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.